Program
upadacitinib
Also written as “Upadacitinib”, “ABT-494” and “Upadacitinib 15 MG [Rinvoq]”.
Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Alopecia Areata, led by 3 companies.
Drug pageUpadacitinib: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 6121 open or running | phase 4since Aug 18, 2022 | Dec 3, 2012 | Nov 2026phase 3 · NCT06389136 |
| CARE ARTHRITISits history only | 22 open or running | phase 4since Jun 6, 2024 | Jun 6, 2024 | May 2027phase 4 · NCT07018206 |
| Modern Biosciencesits history only | 11 open or running | phase 1since Apr 8, 2024 | Apr 8, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 47 earlier studies, Oct 9, 2013 to Aug 22, 2023.
- Jun 9, 2016Named upadacitinibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ABT-494
- Nov 1, 2023Phase 3 study in VitiligoNCT06118411 · 614 enrolled · United States, Argentina, Belgium and more
- Mar 19, 2024Phase 3 study in Crohn DiseaseNCT06332534 · 111 enrolled · United States, Australia, Belgium and more
- Apr 25, 20242 phase 3 studies in Dermatitis, AtopicNCT06389136, NCT06390722
- Jun 12, 2024Phase 3 study in Dermatitis, AtopicNCT06461897 · 699 enrolled · United States, Argentina, Australia and more
- Nov 21, 2024Phase 3 study in Dermatitis, AtopicNCT06701331 · 99 enrolled · Japan
- Jun 10, 2025Phase 3 study in Alopecia AreataNCT07023302 · 125 enrolled · Japan
- Feb 17, 2026Phase 1 study in Healthy VolunteerNCT07425899 · 16 enrolled · United States
- Aug 11, 2026Phase 3 study in Alopecia AreataNCT07772492 · 300 planned · United States, Australia, Japan and more
- Sep 22, 2026Phase 1 study in Healthy VolunteersNCT07843693 · 60 planned · United States
- Oct 16, 2026Primary completion moved from 2027-06 to 2031-01Date moved laterphase 3 · +43 months · NCT06332534
- Oct 16, 2026Primary completion moved from 2026-08 to 2026-11Date moved laterphase 3 · +3 months · NCT06389136
- Oct 21, 20262 phase 3 studiesNCT07896434, NCT07933211
- Oct 23, 2026Phase 2 study in Arthritis, RheumatoidNCT07904754 · 250 planned
- Nov 13, 2026Primary completion moved from 2028-03 to 2028-08Date moved laterphase 3 · +5 months · NCT05889182
Ahead
- Nov 2026Primary completion: phase 3 study in Dermatitis, AtopicNCT06389136
- Dec 2026Primary completion: phase 1 study in Healthy VolunteersNCT07843693
- Jan 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06701331
- Mar 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05843643
TargetBeta
“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
The newest 60 of 61 AbbVie leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933211Scleroderma, Systemic | 3 | Not yet recruiting | Jun 2035 | 580 |
| NCT07904754Arthritis, Rheumatoid | 2 | Not yet recruiting | Jul 2029 | 250 |
| NCT07896434Non-Segmental Vitiligo | 3 | Not yet recruiting | Aug 2032 | 154 |
| NCT07843693Healthy Volunteers · United States | 1 | Recruiting | Dec 2026 | 60 |
| NCT07772492Alopecia Areata · United States, Australia, Japan and more | 3 | Recruiting | Mar 2032 | 300 |
| NCT07425899Healthy Volunteer · United States | 1 | Completed | Jun 5, 2026 | 16 |
| NCT07023302Alopecia Areata · Japan | 3 | Active, not recruiting | Feb 2029 | 125 |
| NCT06701331Dermatitis, Atopic · Japan | 3 | Active, not recruiting | Jan 2027 | 99 |
| NCT06461897Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 2029 | 699 |
| NCT06390722Dermatitis, Atopic | 3 | Withdrawn | Jan 5, 2026 | 0 |
| NCT06389136Dermatitis, Atopic · United States, Canada, Colombia and more | 3 | Active, not recruiting | Nov 2026 | 184 |
| NCT06332534Crohn Disease · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jan 2031 | 111 |
| NCT06118411Vitiligo · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Mar 2028 | 614 |
| NCT06012240Alopecia Areata · United States, Argentina, Australia and more | 3 | Recruiting | Apr 2030 | 1,500 |
| NCT05889182Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 2028 | 1,328 |
| NCT05843643Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 2027 | 1,014 |
| NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | Jul 15, 2026 | 487 |
| NCT05782907Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Active, not recruiting | Aug 2028 | 122 |
| NCT05609630Arthritis, Juvenile · United States, Argentina, Australia and more | 3 | Recruiting | Jun 2029 | 90 |
| NCT05601882Dermatitis, Atopic · United States, Australia, Belgium and more | 3 | Completed | Mar 19, 2024 | 920 |
| NCT05507580Dermatitis, Atopic · Australia, Belgium, Bulgaria and more | 4 | Completed | Jul 11, 2024 | 461 |
| NCT04927975Vitiligo · United States, Canada, France and more | 2 | Completed | Jan 13, 2023 | 185 |
| NCT04666675Dermatitis, Atopic | 3 | Withdrawn | Mar 23, 2021 | 0 |
| NCT04451772Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Jan 3, 2024 | 185 |
| NCT04430855Hidradenitis Suppurativa · United States, Canada, Japan and more | 2 | Completed | Apr 22, 2021 | 68 |
| NCT04195698Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Sep 11, 2023 | 475 |
| NCT04169373Spondylarthritis · United States, Argentina, Australia and more | 3 | Completed | Sep 2, 2021 | 734 |
| NCT04161898Takayasu Arteritis · Argentina, Brazil, China and more | 3 | Active, not recruiting | Aug 2028 | 56 |
| NCT03978520Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Jan 19, 2022 | 341 |
| NCT03823378Arthritis, Rheumatoid · Belgium, Canada, Czechia and more | 2 | Terminated | Sep 9, 2020 | 97 |
| NCT03738397Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Aug 27, 2020 | 673 |
| NCT03725202Giant Cell Arteritis · United States, Australia, Austria and more | 3 | Completed | Feb 6, 2024 | 429 |
| NCT03725007Arthritis, Juvenile · United States, Canada, Germany and more | 1 | Active, not recruiting | Dec 2028 | 124 |
| NCT03682705Arthritis, Rheumatoid · United States, Belgium, Canada and more | 2 | Completed | Mar 26, 2020 | 242 |
| NCT03661138Dermatitis, Atopic · Japan | 3 | Completed | Aug 19, 2022 | 272 |
| NCT03653026Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Jan 14, 2021 | 522 |
| NCT03646604Dermatitis, Atopic · United States, Norway, Puerto Rico | 1 | Completed | Aug 29, 2024 | 35 |
| NCT03607422Dermatitis, Atopic · United States, Australia, Austria and more | 3 | Completed | Mar 11, 2021 | 912 |
| NCT03569293Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Completed | Jan 6, 2021 | 912 |
| NCT03568318Dermatitis, Atopic · United States, Australia, Austria and more | 3 | Active, not recruiting | Feb 16, 2021 | 1,533 |
| NCT03345849Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Oct 15, 2021 | 526 |
| NCT03345836Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Aug 11, 2021 | 624 |
| NCT03345823Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 2027 | 747 |
| NCT03178487Spondylitis, Ankylosing · United States, Australia, Belgium and more | 2 | Completed | Jan 21, 2019 | 187 |
| NCT03104400Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Completed | Sep 26, 2019 | 1,705 |
| NCT03104374Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | Jul 23, 2019 | 642 |
| NCT03006068Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2027 | 950 |
| NCT02955212Arthritis, Rheumatoid · Brazil, China, Korea, Republic of | 3 | Completed | Aug 14, 2019 | 338 |
| NCT02925117Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | Aug 10, 2017 | 167 |
| NCT02819635Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Dec 13, 2021 | 1,302 |
| NCT02782663Crohn Disease · United States, Belgium, Canada and more | 2 | Completed | Jul 18, 2025 | 107 |
| NCT02720523Arthritis, Rheumatoid · Japan | 3 | Completed | Aug 3, 2017 | 197 |
| NCT02706951Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Oct 2, 2017 | 648 |
| NCT02706873Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Mar 15, 2018 | 1,002 |
| NCT02706847Arthritis, Rheumatoid · United States, Australia, Austria and more | 3 | Completed | Apr 3, 2017 | 499 |
| NCT02675426Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Apr 21, 2017 | 661 |
| NCT02365649Crohn Disease | 2 | Completed | Nov 25, 2016 | 220 |
| NCT02066389Arthritis, Rheumatoid · United States, Bulgaria, Chile and more | 2 | Completed | Jul 2, 2015 | 300 |
| NCT02049138Arthritis, Rheumatoid · United States, Belgium, Bulgaria and more | 2 | Completed | Jul 29, 2021 | 493 |
| NCT01960855Arthritis, Rheumatoid | 2 | Completed | Jul 2015 | 276 |
How it is read
Names in the registry
- “Upadacitinib”, 54 entries
- “ABT-494”, 4 entries
- “Upadacitinib 15 MG [Rinvoq]”, 2 entries
- “Upadacitinib (ABT-494)”, 2 entries
- “Upadacitinib 15mg Dose”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 15 studies
- Arthritis, Rheumatoid, 14 studies
- Crohn Disease, 6 studies
- Colitis, Ulcerative, 4 studies
- Alopecia Areata, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.